Jean Y. Tang MD PhD
Academic Appointments
- Assistant Professor - Med Center Line, Dermatology
- Member, Bio-X
- Member, Stanford Cancer Institute
Key Documents
Contact Information
-
Clinical Offices
Medical Dermatology 450 Broadway ST Pav B FL 4 MC 5338 Redwood City, CA 94063 Tel Work (650) 723-6316 Fax (650) 721-3476
- Academic Offices
Personal Information Email Tel (650) 721-7152Alternate contact Olena Mykhaylichenko Administrative Associate Email Tel Work 650-721-7193Not for medical emergencies or patient use
Professional Overview
Clinical Focus
- Cancer> Cutaneous (Dermatologic) Oncology
- Skin Cancer
- Epidemiology
- Clinical Trial
- Dermatology
- Basal Cell Carcinoma
Honors and Awards
- Clinical Investigator Award, Damon Runyon (July 1 2011 - July 2014)
- K23 Career Development Award, National Institutes of Health (2009 - 2013)
- Health Services Investigator Award, American Skin Association (2009)
- KL2 Clinical and Translational Science Institute Career, National Institutes of Health (2006-2009)
- Young Investigator Award, Prevent Cancer Organization (2007-2009)
Professional Education
| Residency: | Stanford University Hospital & Clinics - Dermatology Department, CA USA (2007) |
| Fellowship: | UCSF - Dept of Epidemiology and Biostatistics CA (2008) |
| Internship: | Santa Clara Valley Medical Center, CA USA (2004) |
| Medical Education: | Stanford University Hospital & Clinics - Dermatology Department, CA USA (2003) |
| Board Certification: | Dermatology, American Board of Dermatology (2007) |
| Fellow: | Univ of Calif, San Francisco, KL2 Clinical Research (2009) |
Community and International Work
- Xeroderma Pigmentosum in Underserved Populations, Guatemala City, Guatemala
Internet Links
Scientific Focus
Current Research Interests
My research focuses on finding new ways to treat and prevent non-melanoma skin cancer. I am committed to bringing laboratory-based insights to benefit our patients. I am interested in these questions:
1. How do we prevent skin cancer?
2. What is the relationship between sunlight, vitamin D, and skin cancer risk?
3. Can we target certain tumor signaling pathways (Hedgehog pathway) to treat basal cell carcinomas - the most common cancer in the US?
Clinical Trials
- Recruiting Arsenic Trioxide in Treating Patients With Basal Cell Carcinoma
- Recruiting Pilot Trial to Evaluate the Effect of Vitamin D on Melanocyte Biomarkers
- Recruiting Vismodegib in Treating Patients With Basal Cell Carcinoma
- Not Recruiting Pilot Biomarker Trial to Evaluate the Efficacy of Itraconazole in Patients w/ Basal Cell Carcinomas
Publications
- Aspirin is associated with lower melanoma risk among postmenopausal Caucasian women: The Women's Health Initiative. Cancer. 2013; (8): 1562-9
- GLI activation by atypical protein kinase C ι/λ regulates the growth of basal cell carcinomas. Nature. 2013; (7438): 484-8
- Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists. Cancer Cell. 2013; (1): 23-34
- Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med. 2012; (23): 2180-8
- Calcium plus vitamin D supplementation and the risk of nonmelanoma and melanoma skin cancer: post hoc analyses of the women's health initiative randomized controlled trial. J Clin Oncol. 2011; (22): 3078-84
- Comment on Basal Cell Carcinoma Rebound After Cessation of Vismodegib in an Individual With Basal Cell Nevus Syndrome. Dermatol Surg. 2013
Help